contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nanexa-receives-extended-gmp-certificate-for-the-new-pilot-plant

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.

Nanexa

Nanexa AB (publ) today announced that the company’s new pilot plant in Uppsala has received certification from the Swedish Medical Products Agency for production of clinical trial material.Nanexa...

<div class="mfn-preamble"><p><strong>Nanexa AB (publ) today announced that the company’s new pilot plant in Uppsala has received certification from the Swedish Medical Products Agency for production of clinical trial material.</strong></p></div><div class="mfn-body"><p>Nanexa has since before a GMP-certificate for small scale production and release of clinical trial material. The new larger pilot plant is designed for larger scale and more efficient production, and also to handle production of toxic as well as biological drug products with the Atomic Layer Deposition technology.</p><p>In June 2022, the Swedish Medical Products Agency made an inspection of Nanexa’s new pilot plant and updated quality system in order to issue a certificate for production and release of clinical trial material. The inspection was made without any major observations and, following the company’s answers and actions in response to outstanding questions, the final approval and certificate was today received.</p><p>“It is very gratifying that our hard work with completion and quality assurance of the pilot plant, and continued GMP compliance, has been carried out successfully and following the time plan. With this certification, we can now produce material for clinical studies, the first one being the phase I study in our own NEX-20 project which is planned to start during the fourth quarter of this year”, said David Westberg, CEO of Nanexa. ”The fact that we now have GMP-certificate for the new pilot plant and a complete quality management system is a further step to bring additional projects into clinical development and very important in discussions with potential partners regarding future projects”.</p></div><div class="mfn-footer mfn-contacts mfn-2376405b3437"><p><strong class="mfn-heading-1">For additional information, please contact:</strong></p><hr><p>David Westberg – CEO, Nanexa AB (publ)&nbsp;<br>Phone: +46 70 942 83 03<br>Email:&nbsp;<a rel="nofollow noopener" href="mailto:david.westberg@nanexa.se">david.westberg@nanexa.se</a><br><a rel="nofollow noopener" href="http://www.nanexa.com/">www.nanexa.com</a><br>Erik Penser Bank is the company’s&nbsp;Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se</p></div><div class="mfn-footer mfn-about mfn-c9ba281e2dde"><p><strong class="mfn-heading-1">About Nanexa AB (publ)</strong></p><hr><p>Nanexa is a pharmaceutical company developing parenteral drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.</p><p>Nanexa’s share is listed&nbsp;on Nasdaq First North Growth Market in Stockholm (NANEXA).</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/0f501351-9ebd-48cf-9331-4acd7143d928/nanexa-receives-extended-gmp-certificate-for-the-new-pilot-plant.pdf" class="mfn-generated mfn-primary">Nanexa receives extended GMP-certificate for the new pilot plant</a></p></div>